This is an old revision of this page, as edited by Beetstra (talk | contribs) at 11:34, 31 October 2011 (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEBI', 'CAS_number').). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
Revision as of 11:34, 31 October 2011 by Beetstra (talk | contribs) (Script assisted update of identifiers for the Chem/Drugbox validation project (updated: 'ChEBI', 'CAS_number').)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff) Pharmaceutical compound| File:Choline alfoscerate.svg | |
| Clinical data | |
|---|---|
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| PubChem CID | |
| ChemSpider | |
| ChEBI | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.044.496  |
| Chemical and physical data | |
| Formula | C8H20NO6P |
| Molar mass | 257.221 g/mol g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
L-Alpha Glycerylphosphorylcholine (Alpha GPC, choline alfoscerate) is a natural choline compound found in the brain and in milk. It is also a parasympathomimetic acetylcholine precursor which may have potential for the treatment of Alzheimer's disease and is used as a nootropic dietary supplement to enhance memory and cognition.
Alpha GPC rapidly delivers choline to the brain across the blood-brain barrier and is a biosynthetic precursor of the acetylcholine neurotransmitter. Alpha GPC is derived from highly purified soy lecithin.
Studies have investigated its efficacy for cognitive disorders including stroke and Alzheimer’s Disease. An Italian multicentre clinical trial on 2,044 patients suffering from recent stroke were supplied alpha-GPC in doses of 1,000 mg/day for 28 days and 400 mg three times per day for the five ensuing months. The trial confirmed the therapeutic role of alpha-GPC on the cognitive recovery of patients based on four measurement scales, three of which reached statistical significance.
Commonly used doses are 300-1,200 mg daily.
References
- De Jesus Moreno Moreno M (2003). "Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial". Clin Ther. 25 (1): 178–93. doi:10.1016/S0149-2918(03)90023-3. PMID 12637119.
{{cite journal}}: Unknown parameter|month=ignored (help) - Parnetti, Lucilla (2007). "Cholinergic precursors in the treatment of cognitive impairment of vascular origin: Ineffective approaches or need for re-evaluation?". Journal of the Neurological Sciences. 257 (1–2): 264–9. doi:10.1016/j.jns.2007.01.043. PMID 17331541.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help) - Barbagallo Sangiorgi G, et al. "Alpha-Glycerophosphocholine in the mental recovery of cerebral ischemic attacks." An Italian multicenter clinical trial. Ann NY Acad Sci 1994; 717:253-69.